Sequential Immunophenotyping Studies Before Treatment and at Relapse of ALL in 37 Patients
| Pretreatment . | Relapse . | No. of Cases (n = 37) . | Average No. of Markers . | |
|---|---|---|---|---|
| Gained . | Lost . | |||
| B | B | 15 | 2 | 1 |
| B + My | B + My | 8 | 2 | 1 |
| T | T | 2 | 0 | 2 |
| B | B + My | 6 | 2 | 0 |
| B + My | B | 2 | 0 | 1 |
| T | CD34, CD45 dim | 1 | 0 | 2 |
| T | Normal | 1 | 0 | 7 |
| B + T | B | 1 | 2 | 3 |
| B + T + My | T + My | 1 | 1 | 1 |
| Pretreatment . | Relapse . | No. of Cases (n = 37) . | Average No. of Markers . | |
|---|---|---|---|---|
| Gained . | Lost . | |||
| B | B | 15 | 2 | 1 |
| B + My | B + My | 8 | 2 | 1 |
| T | T | 2 | 0 | 2 |
| B | B + My | 6 | 2 | 0 |
| B + My | B | 2 | 0 | 1 |
| T | CD34, CD45 dim | 1 | 0 | 2 |
| T | Normal | 1 | 0 | 7 |
| B + T | B | 1 | 2 | 3 |
| B + T + My | T + My | 1 | 1 | 1 |